Accuray Incorporated
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Accuray Incorporated designs, develops, manufactures, and sells advanced radiosurgery and radiation therapy systems for the treatment of tumors and certain neurological conditions. The company's core products include the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy platform used for treating primary and metastatic tumors outside the brain, including tumors near the spine and in organs such as the breast, kidney, liver, lung, pancreas, and prostate. Accuray also offers the TomoTherapy platform, including the Radixact System, which delivers stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity-modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), and adaptive radiation therapy (ART). The company's products aim to provide precise, personalized radiation treatments to improve clinical outcomes while expanding the curative potential of radiotherapy. Accuray operates globally with more than 1,000 installed systems across the Americas, Europe, the Middle East, India, Africa, Japan, China, and the Asia-Pacific region, with manufacturing facilities in the United States and China. Founded in 1990 and headquartered in Madison, Wisconsin, Accuray serves healthcare providers and hospitals worldwide. Recent major developments include Accuray's strategic partnership with Cognizant to support the deployment of the SAP S/4HANA enterprise resource planning system aimed at enhancing operational efficiencies through improved data analytics and process optimization across sales, procurement, manufacturing, distribution, installation, and service functions. The company has also expanded its global footprint with new installations and treatments, such as the first stereotactic body radiation therapy treatments using the CyberKnife system in Melbourne, Australia. Regulatory milestones include recent approvals from China's National Medical Products Administration for the Radixact SynC System and CyberKnife S7, supporting Accuray’s growth strategy to increase patient access to advanced radiotherapy technologies. Additionally, Accuray inaugurated an Innovation & Partnership Hub in Genolier, Switzerland, to foster collaborative cancer treatment innovations. Its latest product efforts focus on automating workflows and enhancing treatment planning tools to improve patient outcomes and deliver more personalized radiotherapy options. Financial performance highlights include a significant year-over-year product revenue increase driven primarily by strong demand in China and growth prospects in other regions such as the EIMEA, supported by ongoing product launches and regulatory approvals for systems like the Helix and Tomo platforms. Accuray operates primarily in the medical technology and radiation oncology industry segment, targeting cancer treatment centers and healthcare providers specializing in oncology. Its product portfolio and strategic collaborations emphasize precision and personalization in cancer care, aiming to improve the quality of life and treatment efficacy for cancer patients globally. The company continues to pursue technology integration and operational excellence to maintain its competitive position in the evolving oncology treatment landscape. This description captures Accuray’s comprehensive product offerings, recent strategic developments, global market presence, and operational initiatives as of late 2025.
Accuray Incorporated Reports Inducement Award Under NASDAQ Listing Rules
Accuray and the University of Wisconsin-Madison Announce Master Research Agreement to Improve Personalized Care for Patients with Cancer
Accuray Incorporated (ARAY) Q3 2026 Earnings Call Transcript
Accuray Reports Fiscal 2026 Third Quarter Financial Results
Accuray to Report Third Quarter Fiscal 2026 Financial Results on May 6, 2026
Accuray (ARAY) to Release Quarterly Earnings on Wednesday
Accuray Appoints Paul Miele as Senior Vice President and Chief Commercial Officer
Short Interest in Accuray Incorporated (NASDAQ:ARAY) Expands By 20.6%
Accuray Q2 Earnings Call Highlights
Accuray Incorporated (ARAY) Q2 2026 Earnings Call Transcript
Accuray Reports Fiscal 2026 Second Quarter Financial Results
Acuitas Investments LLC Raises Stake in Accuray Incorporated $ARAY
Accuray to Report Second Quarter Fiscal 2026 Financial Results on February 4, 2026
Accuray (NASDAQ:ARAY) & Check-Cap (NASDAQ:CHEK) Critical Analysis
Radiation Therapy-Focused Accuray Details Workforce Reduction, Outsourcing In Major Transformation Push
Radiation Therapy-Focused Accuray Details Workforce Reduction, Outsourcing In Major Transformation Push
Accuray announces first phase of comprehensive strategic, operational, and organizational transformation plan; company expects first phase to improve annualized operating profitability by approximately $25 million and set the stage for renewed growth
Financial Review: Accuray (NASDAQ:ARAY) & Mesa Laboratories (NASDAQ:MLAB)
Accuray's Latest Transformation Attempt Could Be Too Little Too Late
Accuray Incorporated (ARAY) Q1 2026 Earnings Call Transcript